FORM PTO-14 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No.: CASE-02138

Serial No.: 08/521,725

URE STATEMENT BY APPLICANT eral Sheets If Necessary)

Applicant: Paul V. Lehmann et al.

(37 CFR § 1.98(b))					Filing Date: 03/21/96		Group Art Unit: 1644				
				U.S. PATENT DOC	UMENTS			730	, ,		
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applica	ant / Patentee	Class	Subclass	Filing Date	7		
M3(1	4,948,442	08/14/90	Ro	y Manns	156	73.1	06/18/85	7		
ארשען	2	5,047,215	09/10/91	Ro	y Manns	422	101	05/30/90	7		
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)											
BI	_ 3	D.E. Smilek et al., "Antigen Recognition and Peptide-Mediated Immunotherapy in Autoimmune Disease," Immunol. Rev. 118:37-71 (1990)									
12/	4	S. Zamvil and L. St	einman, "The T Lyn	nphocyte In Experimen	ntal Allergic Encephalomye	litis," Ann. Rev.	Immunol. 8:579	9-621(1990)]		
m	. 5	J. Kimball, Introduction to Immunology (2d Edition) Macmillan Publishing, NY p. 488 (1986)									
M(/	6	Goodman and Gilman's, The Pharmacological Basis of Therapeutics (8th Edition), Pergamon Press (p.1270)									
121	7	I. Roitt et al., Immunology section 8.9, Gower Medical Publishing, London (1985)									
Par/	8	B. Katzung, Basic & Clinical Pharmacology (5th Edition), Appleton & Lange, Norwalk, Ct. p. 537 (1992)									
mo7/	9	R.R. Caspi et al., "A New of Autoimmune Disease, Experimental Autoimmune Uvcoretinitis Induced in Mice with Two Different Retinal Antigens," J. Immunology 140:1490-1495 (1988)									
MI	10	B. Marshall, "Unidentified Curved Bacilli on Gastric Epithelium in Active Chronic Gastritis," Lances 1:1273-1275 (1983)									
my/	11		A. Lee et al., "Isolation of a Spiral-Shaped Bacterium from the Cat Stomach," Infect. Immun. 56:2843-2850 (1988)								
M)	12	B.J. Paster et al., "Phylogeny of Helicobacter felis sp. nov., Helicobacter mustelae, and Related Bacteria," Int'l. J. Sys. Bacteriol. 41:31-38 (1989)									
MB1/	13	E.R. Einstein et al., "Protective Action of the Encephalitogen and Other Basic Proteins in Experimental Allergic Encephalomyelitis," Immunochemistry 5:567-575 (1968)									
iss /	14	S. Waksal, "Immunomodulation: Immunopotentiation, Tolerance, and Immunosuppression," Immunology II, W.B. Saunders Company, Philadelphia (Ed. J.A. Bellanti) pp. 243-250 (1978)									
my/	15	C.W.M. Adams, "The General Pathology of Multiple Sclerosis: Morphological and Chemical Aspects of the Lesions," Multiple Sclerosis Pathology, Diagnosis, and Management, [J. Hallpike et al. (Eds.)] (London: Chapman & Hall) Chapter 8 pp.203-240(1983)									
MI	16	S. Liebowicz, "The Immunology of Multiple Sclerosis," Multiple Sclerosis Pathology, Diagnosis, and Management, [J. Hallpike et al. (Eds.)] (London: Chapman & Hall) Chapter 12 pp.379-412 (1983)									
	17								Ew(or		
B11	18	Merck Manual, "Hematology and Oncology," 16th ed., p. 1292 (1992)							1		
M)/	19	R.J. Trauger, "Effect of Immunization with Inactivated gp-120-Depleted Human Immunodeficiency Virus Type 1 (HIV-1) Immunogen on HIV-1 Immunity, Viral DNA, and Percentage of CD4 Cells," J. Infectious Dis. 169:1256-64 (1994)									
131/	20	R.R. Caspi et al. "Endogenous Systemic IFN-y Has a Protective Role against Ocular Autoimmunity in Mice," J. of Immunology 152:890-899 (1994)							1		
Y31/	21	G. Pialoux et al., "A Prime-Boost Approach to HIV Preventative Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) followed by a Recombinant Glycoprotein 160 (MN/LAI)," Aids Research and Human Retroviruses 11:373-381(1995)									
	22	Swicekosz er al., "Antibody response in the prevention and induction of experimental affergic encephalomyelitis (EAE) in Lewis rats," Immunotogy pp. 814 (abstract)									
31	23	Selected methods in cellular immunology, Mishell and Shiigi, eds., W.H. Freeman and Co., San Francisco, pp.467 (1980)									
121/	24	"Difco Manual: Dehydrated culture media and reagents for microbiology", 10th ed. Difco Lab. Detriot, MI p.67-68, 468 (1984)									
mI	25	Merck Manual, 16th ed., pp 1106-1113, 1305-1312, 1487-1490 and 1900-1901 (1992)									
731/	26		· · · · · · · · · · · · · · · · · · ·			nhalomielitie# (Saignes 351.430	432 (1001)	1		
135/	27	Offner et al., "T cell receptor peptiede therapy triggers autoregulation of experimental encephalomyelitis" Science 251:430-432 (1991) Vandenbark et al., "Immunization with a synthetic T cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis" Nature 341:541-544 (1989)									
caminer:	6)	- 1.2	5 41.541-544 (1		Date Considered:	4/25	1		1		
					mance and not considered.				1		

		i som i		,	Sheet 2 of 2				
FORM PTO-16 (Modified)	449	DOT .	U.S. Department of Commerce Patent and Trademark Office	Attomey Docket No.: CASE-02138	Serial No.: 08/621,725				
INFC	DRMATN	OSE Several Sheets If	TEMENT BY APPLICANT Necessary)	Applicant: Paul V. Lehmann et al.					
(37 CFR § 1.9	/8(b))		,	Filing Date: 03/21/96	Group Art Unit: 1644				
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)									
	28	Raine, C.S. (1983, Multiple Sclenosis - Rathology, Diagnosis, and Management, Je-Hallpike, C-W.M. Adams, W.W. Fourtelotte, (Eds.) (London Chapman & Hall)(1983)							
	29	E. Alvord, Experimental Alleggic Encephalomyolisis: A Useful Model for Multiple Sclerosis, Progress in Clinical and Biological Research, E.C. Alvord et al. (Eds.) (New York, NY) (1984)							
135/	30	Viselli et al., Detection and quantitation of interleuken-2 from individual cells, J. Immun. Methods 125:115-124 (1989)							
	31	MV. Blasser, Prin. Pract. Infect. Dis., pp. 3-10 (1991)							
Examiner:		<u> </u>		Date Considered:	125/2004				
EXAMINER:		itial citation considered. I	Draw line through citation if not in confo applicant.	formance and not considered. Include cop	by of this form				

RECEIVED

OCT 2 7 2003

TECH CENTER 1600/2900